Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Johnson & Johnson Says Will Pay $39M, As Well As An Additional ~$1.5M

Legal
News

Johnson & Johnson Says Will Pay $39M, As Well As An Additional ~$1.5M

-Reuters

byBenzinga Newsdesk

September 1, 2022

1 minute read

-Reuters

SiriusPoint Q4 EPS $(0.17) Misses $0.47 Estimate, Sales $673.60M Up From $398.00M YoY

By Benzinga Newsdesk

February 23, 6:23 PM

SiriusPoint (NYSE:SPNT) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $0.47 by 136.17 percent. This is a 80.68 percent increase over losses of $(0.88) per share from the

SPNT

XS Financial’s Q3 Report Shows Consistent Growth With 108% YoY Increase In Revenue

By Maureen Meehan

November 28, 7:08 PM

XS Financial Inc. (CSE: XSF) (OTCQB: XSHLF), a specialty finance company providing CAPEX and equipment financing solutions to US cannabis companies reported its financial results late Monday for the third quarter ended September 30, 2022.

CSE:XSF

PennantPark Floating Rate Capital Ltd. Priced 4M Share Public Offering of Common Stock @$12.40/Share

By Charles Gross

August 9, 5:54 AM

PennantPark Floating Rate Capital Ltd.

PFLT

Syros Shares Soar As FDA Grants Orphan Drug Status To Pancreatic Cancer Candidate

By Ragothaman Srinivasan

September 13, 4:23 PM

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Syros Pharmaceuticals (NASDAQ: SYRS) lead candidate SY-5609 for the treatment of pancreatic cancer.

SYRS

Johnson & Johnson Says Will Pay $39M, As Well As An Additional ~$1.5M

Related Posts

SiriusPoint Q4 EPS $(0.17) Misses $0.47 Estimate, Sales $673.60M Up From $398.00M YoY

XS Financial’s Q3 Report Shows Consistent Growth With 108% YoY Increase In Revenue

PennantPark Floating Rate Capital Ltd. Priced 4M Share Public Offering of Common Stock @$12.40/Share

Syros Shares Soar As FDA Grants Orphan Drug Status To Pancreatic Cancer Candidate